Skip to main content

Heart Failure clinical trials at UCSF
21 in progress, 9 open to new patients

  • Barostim Therapy for Heart Failure

    open to eligible people ages 21 years and up

    The purpose of this trial is to develop valid scientific evidence for safety and effectiveness of Baroreflex Activation Therapy® with the BAROSTIM NEO® System in subjects with heart failure, defined as New York Heart Association (NYHA) functional class III and left ventricular ejection fraction (LVEF) ≤ 35% despite being treated with the appropriate heart failure guideline directed therapy, excluding subjects eligible for or actively receiving Cardiac Resynchronization Therapy (CRT).

    Fresno, California and other locations

  • Clinical Trial to Evaluate the the ReliantHeart HeartAssist 5® VAD System in Patients Awaiting Heart Transplantation

    open to eligible people ages 18 years and up

    The purpose of the study is to evaluate the safety and effectiveness of the ReliantHeart HeartAssist 5® VAD System in patients listed for heart transplantation and at risk of death from refractory end-stage heart failure.

    San Francisco, California and other locations

  • Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus

    open to all eligible people

    The primary goal of the trial is to compare two different Patent Ductus Arteriosus (PDA) treatment approaches: 1) an "early treatment" approach or 2) a "conservative" approach. For the purposes of the study infants will be enrolled if they are delivered before 28 weeks gestation and have a moderate/large PDA present at 5-7 days after birth. The hypothesis is: treatment of a moderate size patent ductus arteriosus (PDA) will decrease the time needed for assisted respiratory support, diuretic therapy, and gavage feeding assistance, in addition to decreasing the incidence of ductus ligations or need for future outpatient cardiology follow-up appointments. The investigators hypothesize that one or more of these benefits will occur without an increase in the time taken to achieve full enteral feedings or in the incidence of necrotizing enterocolitis (NEC) or spontaneous intestinal perforations (SIP).The investigators will be comparing the effectiveness of early pharmacologic treatment with a control group of conservatively managed infants who will only receive treatment if they meet specific criteria for "rescue treatment".

    San Francisco, California and other locations

  • EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

    open to eligible people ages 18 years and up

    The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

    San Francisco, California and other locations

  • Mechanical Support Measures of Adjustment and QOL

    open to eligible people ages 19 years and up

    The purpose of this study is to develop a measurement system to assess adjustment to mechanical circulatory support (MCS) (also referred to as a ventricular assist device [VAD]) and health-related quality of life (HRQOL) in patients with advanced heart failure who receive a VAD. This investigators refer to this measurement system as Mechanical Circulatory Support: Adjustment and Quality of Life (MCS A-QOL).

    San Francisco, California and other locations

  • Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy

    open to eligible people ages 50 years and up

    This study is a prospective, multi-center, randomized, double-blind placebo-controlled study of subjects receiving the HM II LVAD as per the current FDA approved indications for use.

    San Francisco, California and other locations

  • Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

    open to all eligible people

    The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

    San Francisco, California and other locations

  • Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF..

    San Francisco, California and other locations

  • The Product Surveillance Registry REVERSE Post Approval Study

    open to all eligible people

    The purpose of the REVERSE Post Approval Study (PAS) is to confirm the benefit observed in the REVERSE and RAFT pivotal studies in "real-world" clinical practice.

    San Francisco, California and other locations

  • e-Diary in Heart Failure

    Sorry, not yet accepting patients

    The purpose of this study is to determine the efficacy and feasibility of using a smartphone application to monitor symptoms and weight in patients with advanced heart failure.

    Concord, California

  • Home Outpatient Monitoring and Engagement to Predict HF Exacerbation

    Sorry, not yet accepting patients

    The HOME PREDICT HF study looks at new ways to predict hospitalizations for heart failure. We will use a set of devices at home and surveys to collect information about patient's health. This study uses the Eureka app, a new study app developed by the University of California, San Francisco. The study is designed to happen remotely, using this application on a patient's smartphone, so that is as convenient as possible to participate.

  • Pressure Variability Study

    Sorry, not currently recruiting here

    The purpose of this study is to understand how the pressure in the pulmonary artery changes under different conditions of posture, respiration and exertion.

    San Fransisco, California and other locations

  • Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

    Sorry, not currently recruiting here

    The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction.

    San Francisco, California and other locations

  • Technology-Based Intervention to Promote Heart Health After Cardiac Rehab (Mobile4Heart)

    Sorry, not yet accepting patients

    The purpose of this study is to determine whether using a mobile app increases adherence to a heart healthy prescription after discharge from a cardiac rehab program.

    Concord, California

  • Attain Performa™ Left Ventricular (LV) Quadripolar Leads Chronic Performance Study

    Sorry, in progress, not accepting new patients

    Lead survivability will be summarized.

    San Francisco, California and other locations

  • Coagulation and Fibrinolysis in Pediatric Insulin Titration Trial (CAF-PINT)

    Sorry, in progress, not accepting new patients

    Project Summary We propose an ancillary study to The Heart and Lung Failure Pediatric Insulin Titration trial (HALF PINT), which is investigating the impact of normalizing blood glucose using insulin infusions on clinical outcomes among children with hyperglycemia and heart and lung failure. In this ancillary study, we will measure plasma levels of inflammatory, coagulation, and fibrinolysis proteins and genotype DNA for polymorphisms among patients enrolled in the HALF PINT trial. The results from this ancillary study will help us to understand potential mechanisms through which normalizing blood glucose provides benefit, which may lead to development of new therapeutic strategies in critically ill children

    Oakland, California and other locations

  • Global Non-interventional Heart Failure Disease Registry

    Sorry, in progress, not accepting new patients

    The clinical characteristics, initial presentation, management, and outcomes of patients hospitalized with new-onset (first diagnosis) heart failure (HF) or decompensation of chronic HF are poorly understood worldwide. REPORT-HF is a global, prospective, and observational HF disease registry designed to characterize patient trajectories longitudinally during and following an index hospitalization for acute HF.

    San Francisco, California and other locations

  • HW006 LATERAL Thoracotomy

    Sorry, in progress, not accepting new patients

    This is a prospective, multi-center,single-arm study that will evaluate the thoracotomy implant technique in up to 145 subjects implanted via thoracotomy with the HeartWare HVAD System and enrolled in the Interagency Registry for Mechanically Assisted Circulatory Support (Intermacs®) protocol and database. All participating centers are current INTERMACS® sites in good standing and follow the INTERMACS® protocol and procedures.

    San Francisco, California and other locations

  • Model 4296 Left Ventricular (LV) Lead Chronic Performance Study

    Sorry, in progress, not accepting new patients

    Lead survivability will be summarized.

    San Francisco, California and other locations

  • Model 4396 Left Ventricular (LV) Lead Chronic Performance Study

    Sorry, in progress, not accepting new patients

    Lead survivability will be summarized.

    San Francisco, California and other locations

  • Use of 3-D Blood Pool Scintigraphy to Guide Left Ventricular Pacing Lead Placement in Patients Requiring Cardiac Resynchronization Therapy

    Sorry, in progress, not accepting new patients

    The purpose of this study is to determine whether multiple gated acquisition (MUGA) guided lead placement improves clinical outcomes for patients needing cardiac resynchronization therapy (CRT) compared to traditional posterolateral left ventricular lead placement.

    San Francisco, California